Alpha-Synuclein Mutants for Seed-Dependent Aggregate Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for detecting alpha-Synuclein aggregates, such as those used in Parkinson's disease diagnosis, suffer from high false-positive rates due to spontaneous aggregation of wild-type alpha-Synuclein, leading to inaccurate and time-consuming results.

Innovation Solution

Development of alpha-Synuclein mutants with reduced self-aggregation ability but capable of aggregating in the presence of a seed, used as substrates for precise detection of alpha-Synuclein protein, oligomers, or aggregates, employing techniques like PMCA and Congo red dot tests.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If wild-type alpha-Synuclein is used as substrate for detection, then the assay can detect alpha-Synuclein aggregates, but spontaneous aggregation occurs leading to false-positive results

Engineering Contradiction:

Improvedetection accuracyVSAvoidfalse-positive rate

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The patent creates mutant copies (E46P and A53P) of the alpha-Synuclein protein that replicate the aggregation properties of pathological forms while eliminating spontaneous aggregation. These mutant substrates serve as faithful copies of disease-associated aggregates without the harmful background noise of wild-type spontaneous aggregation, enabling specific detection of pathological forms.

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent modifies specific amino acid parameters at positions 46 and 53 (E46P and A53P mutations) to fundamentally change the aggregation behavior of alpha-Synuclein. These parameter changes eliminate spontaneous aggregation while preserving seed-dependent aggregation capability, creating a substrate with optimized detection properties that resolves the false-positive problem.

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If current detection methods are used, then alpha-Synuclein aggregates can be detected, but sensitivity is inadequate for early detection of synucleinopathies

Engineering Contradiction:

Improvedetection sensitivityVSAvoidearly detection capability

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent performs preliminary modification of the substrate by introducing E46P and A53P mutations that pre-program the protein for high-sensitivity seed-dependent aggregation. This preliminary action creates a substrate that is primed to respond specifically to pathological seeds with high amplification, enabling detection at extremely early stages before significant neuronal loss occurs.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The mutant alpha-Synuclein substrates act as intermediaries that amplify the signal from minimal pathological seeds. The E46P and A53P mutants serve as highly sensitive mediators that can detect and amplify even trace amounts of pathological aggregates, translating undetectable early-stage pathology into measurable signals through controlled aggregation amplification.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If wild-type alpha-Synuclein is used, then aggregation can occur for detection, but it aggregates spontaneously without seed dependency

Engineering Contradiction:

Improveaggregation efficiencyVSAvoidseed dependency

Core Design Contradiction:

ProductivityVSMeasurement precision

Solution Approach 1:

The patent inverts the normal aggregation logic by creating mutants that cannot aggregate spontaneously but can be induced to aggregate by seeds. Instead of using wild-type that aggregates freely and requiring seed suppression, the E46P and A53P mutants are designed with reversed properties: they are aggregation-inert unless activated by pathological seeds, making seed dependency the default rather than the exception.

Inventive Principle:

Principle #13The other way round (Inversion)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The mutants enable highly specific and sensitive detection of alpha-Synuclein aggregates at low concentrations, allowing early-stage diagnosis of synucleinopathies like Parkinson's disease with improved accuracy and efficiency.

Implementation Method 1

The E46P and A53P mutants provide a highly specific and sensitive assay for detecting alpha-Synuclein aggregates

Methodology Applied

Scientific EffectProtein aggregation: Coagulation

Implementation Method 2

enabling precise and early detection of alpha-Synuclein oligomers and aggregates

Methodology Applied

Scientific EffectAmyloid formation: Coagulation

Implementation Method 3

with a sensitivity of 100% and specificity of 87.5% using the Congo Red Dot test

Methodology Applied

Scientific EffectCongo Red binding: Absorption (physical)

Data Source

PatentUS12618856B2Alpha-synuclein mutants and uses thereof

Publication Date: 2026.05.05 INDIAN INSTITUTE OF TECHNOLOGY BOMBAY

AI summary

Alpha-Synuclein mutants and uses thereof are disclosed herein. The mutants of the present invention are non-self-aggregating forms of Alpha-Synuclein which make them a suitable candidate for use as substrates in aggregation assay for evaluating the presence of misfolded α-Syn protein. Also disclosed are kits and method for detection of synucleinopathies in individuals, using the mutants of the present invention.